echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > BINidanib China approved for treatment of scleronopathic interstitial lung disease

    BINidanib China approved for treatment of scleronopathic interstitial lung disease

    • Last Update: 2020-06-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Currently, The ® of Vegat has been approved for the treatment of iexclusivetrictive pulmonary fibrosis (IPF) in more than 70 countries (including China) and has been approved in 15 countries for the treatment of interstitial pulmonary disease (SSc-ILD) associated with systemic sclerosis, and has been shown to slow the progression of the disease by slowing the annual decline in lung function (forced lung capacity)systemic sclerosis (SSc), also known as sclerotic disease, is a rare autoimmune disease that affects multiple organs of the body and cannot be cured, causing scarring (fibrosis) in the skin and internal organs (e.gheart, lungs, digestive tract and kidneys)Scleroderma occurs in the lungs, which can cause interstitial lung disease, known as systemic sclerosis-related interstitial pulmonary disease (SSc-ILD), and about 25% of sclerodertic patients experience significant lung damage within 3 years of diagnosisSSc-ILD is a progressive lung disease in which many patients are asymptomatic in the early stages, but have a poor prognosis and low survival ratesIt is a key driver of death in patients with scleronosis (SSc)Source: Bollinger Ingham
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.